Upcoming Event: Pharma China Annual Forum 2016 on March 18 in Shanghai
3/11/2016
Event: Pharma China Annual Forum 2016 – Confronting Healthcare Challenges in China
Organizer: Pharma China
Sponsors: RDPAC, TBD
Supporting Partner: Pharma China Training Institute (PCTI)
Date: 9 AM to 5:15 PM, March 18, 2016
Venue: Le Royal Meridien Shanghai (上海世贸皇家艾美酒店), Shanghai, China
Contact: Jenny Wang or David Xue
Tel: +86 10 84476010
Cell: +86 18601267831
Fax: +86 10 84476110
Introduction
The Chinese pharmaceutical sector growth slowed further in 2015 to around 10% under the shadow of numerous challenges mostly stemmed from the troubled Chinese economy, regulatory shakeups, cost containment measures and healthcare reform turbulences.
There is no doubt the healthcare reform will go on with unchanged ambitions. In reality, with tax and other revenues drying up and under threat of BMI system deficit amid a slowing economy, local governments are pressured by both the central government and the public to do more with less. Despite its superficial goals, the healthcare reform has so far mostly been hijacked by containment of drug costs and no longer about improving efficiency and fixing structural flaws.
Pushed to the corner, drug companies are now at the brink of business bottomlines. However, the trend of irrational cost containment is expected to intensify further in 2016, with the central government upholding the radical healthcare reform experiment in Sanming City of Fujian Province as a model for national reference.
The pharma e-commerce sector has been brewing major revolutionary developments pending official liberalization of online prescription drug sales. Under growing pressure from aggressive moves by e-commerce giants to enter drug distribution, leading pharma distributors rushed to reposition themselves to secure presence in the sector.
In the meantime, the recent CFDA’s move to elevate drug quality and reform drug approval system provides a ray of future hope for MNCs. With a better policed pharmaceutical industry aligned to rational cost structures, MNCs can expect to compete with domestic companies on a more leveled ground in future and fill market vacuum from exiting irregular players. The real questions are that, with the world’s largest population, what kind of healthcare solution and product mix China can and should get for merely 5%-6% of GDP? Is the country willing or able to pay more for better drugs and healthcare?
The Chinese economy and its healthcare system are in transition. This requires pharma companies to recalibrate their strategies and business models.
Chinese experts warned recently that the pharma industry is facing a more complex marketplace in 2016. There will be lots of uncertainties, unbalances and frailty ahead. The future outlook is mixed, while most analysts agree that the market will keep on growing, but at a slower rate, continuing the trend which started two years ago.
The Pharma China Annual Forum 2016 is an English language annual pharma industry event oriented for foreign drug companies in China. The event’s emphasis is on healthcare policies, drug regulations, market access and strategic issues as well as potential impacts of latest and upcoming policy changes on the Chinese pharma industry. In addition, contemporary trends of M&As, R&D and licensing, business hotspots and e-commerce, as well as future market outlook will be explored and discussed.
At least 12 leading experts will share their knowledge, insights and expertise. The presentation will be followed by an interactive panel discussion with speakers.
Fee (covering attendance, lunch and refreshments)
CNY 6,000 – Pharma China subscribers and employees of RDPAC member companies
CNY 6,800 – All other non-subscribers of Pharma China
Sponsorship opportunities
Please contact us about sponsorship packages for refreshments and after-event cocktail.
Registration
Spaces are limited to 80 participants and priority is given to Pharma China subscribers. Please contact:
David Xue
Tel: +86 10 8530-0937 Cell: +86 18601267831
Email: dxue@pharmaguys.com
Jenny Wang
Tel: +86 10 8447-6010 Fax: +86 10 8447-6110